It can be hard living with MS, especially when facing frequent relapses or when you are experiencing increased disability despite being on treatment. At times like these it's important to talk to your doctor. It may be time to consider another therapy. One thing you'll want to know is that Rebif® (interferon beta-1a) has been proven effective against MS in three important ways.


The PRISMS* Study, the largest study of interferon beta-1a ever conducted in relapsing-remitting MS, proved that Rebif 44 mcg three times per week effectively reduced relapses and delayed progression of disability versus placebo over a two-year period.

The EVIDENCE† Study, a completed head-to-head comparative study of MS treatments, showed that people taking the higher, more frequent dosing of Rebif — 44 mcg three times a week — were more likely to remain relapse-free than people treated with Avonex® (interferon beta-1a) 30 mcg once a week. This was proven at 24 and 48 weeks, and the results were maintained through the completion of the study (average 64 weeks).


People in the PRISMS* Study underwent MRI†† scans twice a year to assess the effect of treatment. In this study, Rebif 44 mcg three times per week significantly reduced the number of new and active T2 lesions versus placebo over a two-year period.

Moreover, the EVIDENCE† Study showed that people taking Rebif 44 mcg three times per week had a significant reduction in MRI activity versus those treated with Avonex 30 mcg once a week — at 24 weeks, 48 weeks, and up to an average of 64 weeks.

††The exact relationship between MRI findings and the clinical status of patients is unknown.


In the PRISMS* Study, Rebif 44 mcg three times per week was proven to significantly delay the progression of disability versus placebo over a two-year period.MORE